Monash IVF GroupMNIVF 76 Days Payable is 130.90 as of Dec. 2025, which is 104% above its 10-year median of 64.05. GuruFocus rates MNIVF with a GF Score™ of 76/100 and a GF Value™ of $0.78. The stock has 8 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Monash IVF Group ranks better than 87.43% on this metric.
The historical rank and industry rank for Monash IVF Group's Days Payable or its related term are showing as below:
MNIVF'
s Days Payable Range Over the Past 10 Years
Min: 33.82 Med: 64.05 Max: 307.52
Current: 307.52
During the past 12 years, Monash IVF Group's highest Days Payable was 307.52. The lowest was 33.82. And the median was 64.05.
MNIVF's Days Payable is ranked better than 87.43% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.87
vs MNIVF: 307.52
Monash IVF Group's Days Payable
declined
from Dec. 2024 (337.82) to Dec. 2025 (130.90).
It may suggest that Monash IVF Groupaccelerated paying its suppliers.
Monash IVF Group Days Payable Related Terms
Monash IVF Group Days Payable Historical Data
* Premium members only.
The historical data trend for Monash IVF Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Monash IVF Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monash IVF Group Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Monash IVF Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Monash IVF Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Monash IVF Group's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monash IVF Group (MNIVF) has a Days Payable of 130.90 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Monash IVF Group and its competitors. This is 104% above median its historical median of 64.05. Over the past decade, Monash IVF Group's Days Payable has ranged from 33.82 to 307.52. According to the industry distribution chart, Monash IVF Group ranks #24 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 12.6%.
Is Monash IVF Group's Days Payable too high?
Monash IVF Group's current Days Payable of 130.90 is 104% above median its 10-year median of 64.05. Over the past 10 years, this metric has ranged from a low of 33.82 to a high of 307.52. The Medical Diagnostics & Research industry median Days Payable is 68.87. Monash IVF Group's value of 130.90 is 90.1% above this industry median. Based on the distribution chart, Monash IVF Group ranks #24 out of 191 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Monash IVF Group has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Monash IVF Group's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Monash IVF Group ranks #24 out of 191 companies for Days Payable. This places Monash IVF Group in the top 13% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.87. Monash IVF Group's value of 130.90 is 90.1% above this benchmark. Historically, Monash IVF Group's own Days Payable has ranged from 33.82 to 307.52 over the past decade. While the company's 10-year median is 64.05 vs. the industry median of 68.87, Monash IVF Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 68.87, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monash IVF Group's current Days Payable of 130.90 is 90.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Monash IVF Group and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 68.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monash IVF Group's current Days Payable is 130.90, which is 104% above median its own 10-year median of 64.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monash IVF Group stock overvalued right now?
Monash IVF Group (MNIVF) has a current Days Payable of 130.90. The stock's GF Value™ is $0.78, compared to a current price of $0.40 — trading 48.7% below its estimated fair value. The current Days Payable is 130.90, which is 104% above median its 10-year median of 64.05 and 90.1% above the Medical Diagnostics & Research industry median of 68.87. Monash IVF Group's overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Monash IVF Group (MNIVF), the current Days Payable is 130.90 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monash IVF Group (MNIVF) Overvalued in 2026?
Based on GuruFocus' analysis, Monash IVF Group stock appears to be undervalued.
The current stock price of $0.40 is trading 48.7% below its estimated GF Value™ of $0.78.
Key valuation signals for MNIVF:
Days Payable: 130.90 (104% above median its 10-year median of 64.05)
GF Value™: $0.78 vs. price of $0.40 (48.7% below fair value)
Industry Position: 90.1% above the Medical Diagnostics & Research median (#24 of 191)
No single metric tells the full story. See the MNIVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monash IVF Group Ltd is a provider of fertility services, specializing in Assisted Reproductive Services (ARS) and genetic care across Australia and South East Asia. The Group operates two main segments: Australia IVF and Ultrasound, which offer ARS, ultrasound, and related women's health services, and International IVF, which provides assisted reproductive care in South East Asia. The majority of revenue is generated from the Australian segment through its brands such as Fertility Solutions, KL Fertility, Monash IVF, Repromed, and others.
76GF Score
Get the complete analysis for MNIVF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNIVF has been successfully added to your 
